EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Wednesday reported a loss of $19.5 million in its third quarter.

The Emeryville, California-based company said it had a loss of 43 cents per share.

The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share.

The drugmaker posted revenue of $25.9 million in the period, surpassing Street forecasts. Five analysts surveyed by Zacks expected $25.1 million.

Adamas shares have increased 88% since the beginning of the year. The stock has more than doubled in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADMS at https://www.zacks.com/ap/ADMS

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News